WuXi AppTec assessing options for gene therapy manufacturing business

Reuters

2024/10/08

Oct 8 (Reuters) - China's WuXi AppTec

said on Tuesday it was assessing options for continuing its cell and gene therapy manufacturing business, WuXi Advanced Therapies, but it has not entered any binding deals regarding the operations.

"There is uncertainty as to whether the company will eventually decide to dispose WuXi ATU, or take other options to retain WuXi ATU and execute other options so that such business can continue to operate," it said in an exchange filing.

(Reporting by Himanshi Akhand in Bengaluru; Editing by Alan Barona)

((Himanshi.Akhand@thomsonreuters.com))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2473565984"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2473565984\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2473565984?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 08:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473565984","market":"sh","top_or_hot":-1,"title":"WuXi AppTec assessing options for gene therapy manufacturing business","media":"Reuters","content":"<html><body><p>Oct 8 (Reuters) - China's WuXi AppTec   </p><p>  said on Tuesday it was assessing options for continuing its cell and gene therapy manufacturing business, WuXi Advanced Therapies, but it has not entered any binding deals regarding the operations.     </p><p>   \"There is uncertainty as to whether the company will eventually decide to dispose WuXi ATU, or take other options to retain WuXi ATU and execute other options so that such business can continue to operate,\" it said in an exchange filing.</p><p> (Reporting by Himanshi Akhand in Bengaluru; Editing by Alan Barona)</p><p>((Himanshi.Akhand@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi AppTec assessing options for gene therapy manufacturing business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi AppTec assessing options for gene therapy manufacturing business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-08 08:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Oct 8 (Reuters) - China's WuXi AppTec   </p><p>  said on Tuesday it was assessing options for continuing its cell and gene therapy manufacturing business, WuXi Advanced Therapies, but it has not entered any binding deals regarding the operations.     </p><p>   \"There is uncertainty as to whether the company will eventually decide to dispose WuXi ATU, or take other options to retain WuXi ATU and execute other options so that such business can continue to operate,\" it said in an exchange filing.</p><p> (Reporting by Himanshi Akhand in Bengaluru; Editing by Alan Barona)</p><p>((Himanshi.Akhand@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2473565984","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473565984","pubTimestamp":1728345680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 8  - China's WuXi AppTec     said on Tuesday it was assessing options for continuing its cell and gene therapy manufacturing business, WuXi Advanced Therapies, but it has not entered any binding deals regarding the operations.        \"There is uncertainty as to whether the company will eventually decide to dispose WuXi ATU, or take other options to retain WuXi ATU and execute other options so that such business can continue to operate,\" it said in an exchange filing. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1141":"生命科学工具和服务","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","BK1583":"高瓴概念","BK1576":"医药外包概念","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","02359":"药明康德","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0052750758.USD":"富兰克林中国基金A Acc","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC"},"translate_title":"药明康德评估基因治疗制造业务的选择","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":1},"content_text":"Oct 8 (Reuters) - China's WuXi AppTec     said on Tuesday it was assessing options for continuing its cell and gene therapy manufacturing business, WuXi Advanced Therapies, but it has not entered any binding deals regarding the operations.        \"There is uncertainty as to whether the company will eventually decide to dispose WuXi ATU, or take other options to retain WuXi ATU and execute other options so that such business can continue to operate,\" it said in an exchange filing. (Reporting by Himanshi Akhand in Bengaluru; Editing by Alan Barona)((Himanshi.Akhand@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}